AB Science SA

AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024

23 9 2024 08:51:06 提供 Nasdaq GlobeNewswire

AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19

07 7 2024 22:56:02 提供 Nasdaq GlobeNewswire

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

28 6 2024 03:31:02 提供 Nasdaq GlobeNewswire

AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS

31 5 2024 07:30:34 提供 Nasdaq GlobeNewswire

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

29 5 2024 09:02:52 提供 Nasdaq GlobeNewswire

AB Science reports its revenues for the year 2023 and provides an update on its activities

15 5 2024 11:16:47 提供 Nasdaq GlobeNewswire

AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036

13 5 2024 09:08:35 提供 Nasdaq GlobeNewswire

AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient

07 5 2024 09:05:45 提供 Nasdaq GlobeNewswire

AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science

02 5 2024 10:14:41 提供 Nasdaq GlobeNewswire

AB Science announces a slight delay in the publication of its 2023 annual financial report

30 4 2024 09:56:04 提供 Nasdaq GlobeNewswire

AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS

03 4 2024 09:08:55 提供 Nasdaq GlobeNewswire

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

13 3 2024 04:58:59 提供 Nasdaq GlobeNewswire

AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development

07 3 2024 06:20:57 提供 Nasdaq GlobeNewswire

AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company

06 3 2024 11:21:09 提供 Nasdaq GlobeNewswire

AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET

01 3 2024 09:07:34 提供 Nasdaq GlobeNewswire

AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET

29 2 2024 02:49:23 提供 Nasdaq GlobeNewswire

AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS

26 2 2024 09:32:14 提供 Nasdaq GlobeNewswire

AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency

26 1 2024 09:01:21 提供 Nasdaq GlobeNewswire

AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis

15 1 2024 09:06:57 提供 Nasdaq GlobeNewswire

AB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease

28 11 2023 10:22:40 提供 Nasdaq GlobeNewswire